Systems biology in drug safety and metabolism: integration of microarray, real-time PCR and enzyme approaches.

The last decade has seen a rapid expansion in the field of functional genomics, due mainly to the global gene expression profiling capabilities provided by techniques, such as microarray analysis. Application of these technologies in fields as diverse as plant research, to public health and environmental sciences, forensic science and drug research, shows the versatility of these tools and the promise they hold for revolutionizing research in the life sciences. In drug discovery, attempts have been made to use functional genomics in target identification and validation, lead selection and optimization, and in preclinical studies to predict clinical outcome. These studies have provided a plethora of data and undoubtedly expanded our understanding of genetic alterations in diseased and non-diseased states, but the benefits that these technologies hold have not yet been fully realized. This review discusses how a comprehensive approach to gene regulation studies, a 'systems biology' approach, is being applied in a drug development setting to address mechanism-based questions and issues raised by regulatory authorities.

[1]  P. A. Covitz.  Class struggle: expression profiling and categorizing cancer , 2003, The Pharmacogenomics Journal.

[2]  P. Goodfellow,et al.  DNA microarrays in drug discovery and development , 1999, Nature Genetics.

[3]  A. Li,et al.  Substrates of human hepatic cytochrome P450 3A4. , 1995, Toxicology.

[4]  C. Klaassen,et al.  Increase in rat liver UDP-glucuronosyltransferase mRNA by microsomal enzyme inducers that enhance thyroid hormone glucuronidation. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[5]  R. Mayer,et al.  Differential effects of phenobarbitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism and cytochrome P-450-binding of phenoxazone and a homologous series of its n-alkyl ethers (alkoxyresorufins). , 1983, Chemico-biological interactions.

[6]  D. Haussler,et al.  A physical map of the human genome , 2001, Nature.

[7]  D. Gerhold,et al.  Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays. , 2001, Physiological genomics.

[8]  T. Brodowicz,et al.  From microarrays to new therapeutic approaches in bladder cancer. , 2003, Pharmacogenomics.

[9]  R. J. Anderson,et al.  Sulfation of iodothyronines by recombinant human liver steroid sulfotransferases. , 1999, Biochemical and biophysical research communications.

[10]  D W Nebert,et al.  P450 genes: structure, evolution, and regulation. , 1987, Annual review of biochemistry.

[11]  C. Wittwer,et al.  Quantitative PCR by Continuous Fluorescence Monitoring of a Double Strand DNA Specific Binding Dye , 1998 .

[12]  S. P. Fodor,et al.  High density synthetic oligonucleotide arrays , 1999, Nature Genetics.

[13]  D. G. Herries,et al.  Post-transcriptional regulation of gene expression in guinea pig tissues , 1980, Nature.

[14]  D. Greenblatt,et al.  In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[15]  T. Kroll,et al.  Monitoring therapy with gene expression profiling reveals physiological differences in drug action. , 2004, Current pharmaceutical design.

[16]  B. Burchell,et al.  4-Nitrophenol UDPglucuronyltransferase (rat liver). , 1981, Methods in enzymology.

[17]  R. Lempicki,et al.  Evaluation of gene expression measurements from commercial microarray platforms. , 2003, Nucleic acids research.

[18]  C. Perou,et al.  Molecular portraits and the family tree of cancer , 2002, Nature Genetics.

[19]  A. Parkinson,et al.  Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. , 1996, Archives of biochemistry and biophysics.

[20]  Andrew L. Lemire,et al.  Comparison of microarray-based mRNA profiling technologies for identification of psychiatric disease and drug signatures , 2004, Journal of Neuroscience Methods.

[21]  Matthias Görlach,et al.  DNA-dependent protein kinase (DNA-PK) phosphorylates nuclear DNA helicase II/RNA helicase A and hnRNP proteins in an RNA-dependent manner. , 2004, Nucleic acids research.

[22]  T. Iyanagi,et al.  Identification and analysis of drug-responsive expression of UDP-glucuronosyltransferase family 1 (UGT1) isozyme in rat hepatic microsomes using anti-peptide antibodies. , 1995, Archives of biochemistry and biophysics.

[23]  Sean Kim,et al.  CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[24]  R Sásik,et al.  Microarray truths and consequences. , 2004, Journal of molecular endocrinology.

[25]  R. Shippy,et al.  Performance evaluation of commercial short-oligonucleotide microarrays and the impact of noise in making cross-platform correlations , 2004, BMC Genomics.

[26]  C. Ioannides,et al.  Induction of cytochrome P-448 activity as exemplified by the O-deethylation of ethoxyresorufin. Effects of dose, sex, tissue and animal species. , 1986, Biochemical pharmacology.

[27]  G. Hardiman.  Microarray technologies 2003 -- an overview. , 2003, Pharmacogenomics.

[28]  Kevin Dobbin,et al.  Effects of pooling mRNA in microarray class comparisons , 2004, Bioinform..

[29]  S Hanash,et al.  Making sense of microarray data to classify cancer , 2003, The Pharmacogenomics Journal.

[30]  M. Morley,et al.  Making and reading microarrays , 1999, Nature Genetics.

[31]  Á. Montoya,et al.  Culture of human hepatocytes from small surgical liver biopsies. Biochemical characterization and comparison with in vivo , 2007, In Vitro Cellular & Developmental Biology.

[32]  R. Lightowlers,et al.  Messenger RNA stability in mitochondria: different means to an end. , 2004, Trends in genetics : TIG.

[33]  Z. Szallasi,et al.  Sequence-matched probes produce increased cross-platform consistency and more reproducible biological results in microarray-based gene expression measurements. , 2004, Nucleic acids research.

[34]  Petri Auvinen,et al.  Are data from different gene expression microarray platforms comparable? , 2004, Genomics.

[35]  E. Fiala,et al.  Induction of UDP-glucuronosyltransferase 1 (UDP-GT1) gene complex by green tea in male F344 rats. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[36]  G. Ferron,et al.  Quantitation of cytochrome P450 mRNA levels in human skin. , 2003, Analytical biochemistry.

[37]  M. Naka,et al.  Target validation in hypoxia-induced vascular remodeling using transcriptome/metabolome analysis , 2003, The Pharmacogenomics Journal.

[38]  M. Murphy,et al.  Current pharmacogenomic approaches to clinical drug development. , 2000, Pharmacogenomics.

[39]  R. Abramson,et al.  Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Paul Shannon,et al.  Comprehensive de novo structure prediction in a systems-biology context for the archaea Halobacterium sp. NRC-1 , 2004, Genome Biology.

[41]  U J Balis,et al.  The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. , 1997, BioTechniques.

[42]  J. Kelsoe,et al.  Functional genomics approaches to understanding brain disorders. , 2002, Pharmacogenomics.

[43]  J. W. Cameron,et al.  Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat. , 1985, Archives of biochemistry and biophysics.

[44]  H. Glatt,et al.  Sulfation of thyroid hormone by estrogen sulfotransferase. , 1999, The Journal of clinical endocrinology and metabolism.

[45]  J. Castell,et al.  Re‐expression of C/EBPα induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells , 1998 .

[46]  R. Valdes,et al.  What is next in pharmacogenomics? Translating it to clinical practice. , 2003, Pharmacogenomics.

[47]  C. W. Fisher,et al.  The effects of cytochrome b5, NADPH-P450 reductase, and lipid on the rate of 6 beta-hydroxylation of testosterone as catalyzed by a human P450 3A4 fusion protein. , 1995, Archives of biochemistry and biophysics.

[48]  D. Botstein,et al.  Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Leroy Hood,et al.  Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. , 2004, Journal of proteome research.

[50]  K. Bock,et al.  Effects of phenobarbital and 3-methylcholanthrene on substrate specificity of rat liver microsomal UDP-glucuronyltransferase. , 1973, Biochimica et biophysica acta.

[51]  Gary Hardiman,et al.  Microarray platforms--comparisons and contrasts. , 2004, Pharmacogenomics.

[52]  T. Ørntoft,et al.  Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics , 2000, FEBS letters.

[53]  D. Slonim,et al.  Transcriptional profiling in cancer: the path to clinical pharmacogenomics. , 2001, Pharmacogenomics.

[54]  D. Waxman,et al.  Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. , 1988, Archives of biochemistry and biophysics.

[55]  Kathy Carroll,et al.  Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes , 2000, Journal of biochemical and molecular toxicology.

[56]  E. Schuetz,et al.  Expression of multiple forms of cytochrome P450 mRNAs in primary cultures of rat hepatocytes maintained on matrigel. , 1993, Molecular pharmacology.

[57]  A. Weeraratna,et al.  Gene Expression Profiling: From Microarrays to Medicine , 2004, Journal of Clinical Immunology.

[58]  J. Lehmann,et al.  The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.

[59]  Kennedy Gc.  The impact of genomics on therapeutic drug development. , 2000 .

[60]  O. Iqbal.  Pharmacogenomics in anticoagulant drug development. , 2002, Pharmacogenomics.

[61]  Kristina Hanspers,et al.  Spotted long oligonucleotide arrays for human gene expression analysis. , 2003, Genome research.

[62]  C. Liddle,et al.  Predicting inductive drug-drug interactions. , 2003, Pharmacogenomics.

[63]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[64]  Thomas J. Liesegang,et al.  The sequence of the human genome. Venter JC,∗ Adams MD, Myers EW, et al. Science 2001;291:1304–1351. , 2001 .

[65]  K. Jain,et al.  Applications of biochip and microarray systems in pharmacogenomics. , 2000, Pharmacogenomics.

[66]  C. Rosenow,et al.  Monitoring gene expression using DNA microarrays. , 2000, Current opinion in microbiology.